Breaking Down Silk Road Medical: 5 Analysts Share Their Views

Silk Road Medical SILK underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $20.0, a high estimate of $23.00, and a low estimate of $18.00. This upward trend is apparent, with the current average reflecting a 60.0% increase from the previous average price target of $12.50.

Diving into Analyst Ratings: An In-Depth Exploration

The perception of Silk Road Medical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Silk Road Medical. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Silk Road Medical compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Silk Road Medical's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Capture valuable insights into Silk Road Medical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Silk Road Medical analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Silk Road Medical

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Silk Road Medical's Economic Impact: An Analysis

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Positive Revenue Trend: Examining Silk Road Medical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.89% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Silk Road Medical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -28.78% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Silk Road Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.29%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Silk Road Medical's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.88%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.5, Silk Road Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: Simplified

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.